Influenza vaccine effectiveness in Europe: Results from the 2022-2023 VEBIS (Vaccine Effectiveness, Burden and Impact Studies) primary care multicentre study

被引：15

作者：

Maurel, Marine ^{[1
]}

Pozo, Francisco ^{[2
,3
]}

Perez-Gimeno, Gloria ^{[2
,3
]}

Buda, Silke ^{[4
]}

Seve, Noemie ^{[5
]}

Oroszi, Beatrix ^{[6
]}

Hooiveld, Mariette ^{[7
]}

Gomez, Veronica ^{[8
]}

Domegan, Lisa ^{[9
]}

Martinez-Baz, Ivan ^{[3
,10
]}

Ilic, Maja ^{[11
]}

Carnahan, Anna Sara ^{[12
]}

Mihai, Maria Elena ^{[13
]}

Martinez, Ana ^{[14
]}

Goerlitz, Luise ^{[4
]}

Enouf, Vincent ^{[15
]}

Horvath, Judit Krisztina ^{[6
]}

Dijkstra, Frederika ^{[16
]}

Rodrigues, Ana Paula ^{[8
]}

Bennett, Charlene ^{[17
]}

Trobajo-Sanmartin, Camino ^{[3
,10
]}

Mlinaric, Ivan ^{[11
]}

Latorre-Margalef, Neus ^{[12
]}

Ivanciuc, Alina ^{[13
]}

Lopez, Aurora ^{[18
]}

Duerrwald, Ralf ^{[19
]}

Falchi, Alessandra ^{[20
]}

Turi, Gergo ^{[6
]}

Meijer, Adam ^{[16
]}

Melo, Aryse ^{[8
]}

O'Donnell, Joan ^{[9
]}

Castilla, Jesus ^{[3
,10
]}

Vucina, Vesna Visekruna ^{[11
]}

Hagey, Tove Samuelsson ^{[12
]}

Lazar, Mihaela ^{[13
]}

Kaczmarek, Marlena ^{[21
]}

Bacci, Sabrina ^{[21
]}

Kissling, Esther ^{[1
]}

机构：

[1] Epiconcept, Paris, France

[2] Inst Hlth Carlos III, Natl Ctr Microbiol, Madrid, Spain

[3] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Madrid, Spain

[4] Robert Koch Inst, Dept Infect Dis Epidemiol, Resp Infect Unit, Berlin, Germany

[5] Sorbonne Univ, INSERM, UMRS 1136, Inst Pierre Louis Epidemiol & Sante Publ IPLESP, Paris, France

[6] Semmelweis Univ, Epidemiol & Surveillance Ctr, Natl Lab Hlth Secur, Budapest, Hungary

[7] Nivel, Utrecht, Netherlands

[8] Inst Nacl Saude Dr Ricardo Jorge, Lisbon, Portugal

[9] HSE Hlth Protect Surveillance Ctr, Dublin, Ireland

[10] Inst Salud Publ Navarra IdiSNA, Pamplona, Spain

[11] Croatian Inst Publ Hlth, Zagreb, Croatia

[12] Publ Hlth Agcy Sweden PHAS, Stockholm, Sweden

[13] Cantacuzino Natl Mil Med Inst Res Dev, Bucharest, Romania

[14] Agencia Salud Publ Catalunya, Subdirecc Gen Vigilancia & Respuesta Emergencias, Barcelona, Spain

[15] Inst Pasteur, Ctr Natl Reference Virus Infect CNR VIR, Paris, France

[16] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands

[17] Univ Coll Dublin, Natl Virus Reference Lab, Dublin, Ireland

[18] Conselleria Sanitat, Valencia, Spain

[19] Robert Koch Inst, Natl Reference Ctr Influenza, Berlin, Germany

[20] Univ Corse, INSERM, Lab Virol, Corte, France

[21] European Ctr Dis Prevent & Control, Stockholm, Sweden

来源：

INFLUENZA AND OTHER RESPIRATORY VIRUSES | 2024年 / 18卷 / 01期

关键词：

Europe; influenza; influenza vaccine; multicentre study; vaccine effectiveness;

D O I：

10.1111/irv.13243

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

BackgroundInfluenza A(H3N2) viruses dominated early in the 2022-2023 influenza season in Europe, followed by higher circulation of influenza A(H1N1)pdm09 and B viruses. The VEBIS primary care network estimated the influenza vaccine effectiveness (VE) using a multicentre test-negative study.Materials and MethodsPrimary care practitioners collected information and specimens from patients consulting with acute respiratory infection. We measured VE against any influenza, influenza (sub)type and clade, by age group, by influenza vaccine target group and by time since vaccination, using logistic regression.ResultsWe included 38 058 patients, of which 3786 were influenza A(H3N2), 1548 influenza A(H1N1)pdm09 and 3275 influenza B cases. Against influenza A(H3N2), VE was 36% (95% CI: 25-45) among all ages and ranged between 30% and 52% by age group and target group. VE against influenza A(H3N2) clade 2b was 38% (95% CI: 25-49). Overall, VE against influenza A(H1N1)pdm09 was 46% (95% CI: 35-56) and ranged between 29% and 59% by age group and target group. VE against influenza A(H1N1)pdm09 clade 5a.2a was 56% (95% CI: 46-65) and 79% (95% CI: 64-88) against clade 5a.2a.1. VE against influenza B was 76% (95% CI: 70-81); overall, 84%, 72% and 71% were among 0-14-year-olds, 15-64-year-olds and those in the influenza vaccination target group, respectively. VE against influenza B with a position 197 mutation of the hemagglutinin (HA) gene was 79% (95% CI: 73-85) and 90% (95% CI: 85-94) without this mutationConclusionThe 2022-2023 end-of-season results from the VEBIS network at primary care level showed high VE among children and against influenza B, with lower VE against influenza A(H1N1)pdm09 and A(H3N2).

引用

页数：12

共 23 条

[1]

[Anonymous], 2009, PROTOCOLS CASE CONTR

[2]

[Anonymous], 2015, I MOVE GENERIC STUDY

[3]

[Anonymous], RECOMMENDED COMPOSIT

[4]

[Anonymous], 2013, The Flu Immunisation Programme 2013/14-Extension to Children

[5]

[Anonymous], 2020, EUROPEAN SCI C APPL

[6]

[Anonymous], 2023, Influenza Virus Characterization: Summary Report, Europe, February 2023

[7] Effects of Confounding Bias in Coronavirus Disease 2019 (COVID-19) and Influenza Vaccine Effectiveness Test-Negative Designs Due to Correlated Influenza and COVID-19 Vaccination Behaviors [J].

Doll, Margaret K. ;

Pettigrew, Stacy M. ;

Ma, Julia ;

Verma, Aman .

CLINICAL INFECTIOUS DISEASES, 2022, 75 (01) :E564-E571

[8]

Flu News Europe, FLU NEWS EUROPE

[9] I-MOVE multicentre case-control study 2010/11 to 2014/15: Is there within-season waning of influenza type/subtype vaccine effectiveness with increasing time since vaccination? [J].

Kissling, E. ;

Nunes, B. ;

Robertson, C. ;

Valenciano, M. ;

Reuss, A. ;

Larrauri, A. ;

Cohen, J. M. ;

Oroszi, B. ;

Rizzo, C. ;

Machado, A. ;

Pitigoi, D. ;

Domegan, L. ;

Paradowska-Stankiewicz, I. ;

Buchholz, U. ;

Gherasim, A. ;

Daviaud, I. ;

Horvath, J. K. ;

Bella, A. ;

Lupulescu, E. ;

O'Donnell, J. ;

Korczynska, M. ;

Moren, A. .

EUROSURVEILLANCE, 2016, 21 (16) :13-24

[10] Influenza vaccine effectiveness estimates in Europe in a season with three influenza type/subtypes circulating: the I-MOVE multicentre case-control study, influenza season 2012/13 [J].

Kissling, E. ;

Valenciano, M. ;

Buchholz, U. ;

Larrauri, A. ;

Cohen, J. M. ;

Nunes, B. ;

Rogalska, J. ;

Pitigoi, D. ;

Paradowska-Stankiewicz, I. ;

Reuss, A. ;

Jimenez-Jorge, S. ;

Daviaud, I. ;

Guiomar, R. ;

O'Donnell, J. ;

Necula, G. ;

Gluchowska, M. ;

Moren, A. .

EUROSURVEILLANCE, 2014, 19 (06) :22-33

← 1 2 3 →